A detailed history of Citigroup Inc transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 20,453 shares of CAPR stock, worth $369,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,453
Previous 11,263 81.59%
Holding current value
$369,994
Previous $53,000 486.79%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.56 - $15.21 $32,716 - $139,779
9,190 Added 81.59%
20,453 $311,000
Q2 2024

Aug 12, 2024

SELL
$4.63 - $7.09 $310,622 - $475,661
-67,089 Reduced 85.63%
11,263 $53,000
Q1 2024

May 10, 2024

BUY
$3.61 - $6.88 $196,939 - $375,331
54,554 Added 229.24%
78,352 $532,000
Q4 2023

Feb 09, 2024

SELL
$2.71 - $5.08 $102,419 - $191,988
-37,793 Reduced 61.36%
23,798 $116,000
Q3 2023

Nov 09, 2023

BUY
$3.42 - $7.85 $210,641 - $483,489
61,591 New
61,591 $210,000
Q2 2022

Aug 10, 2022

SELL
$2.89 - $4.51 $57 - $90
-20 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$2.83 - $5.68 $56 - $113
20 New
20 $0

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $440M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.